- Home
- GVH vs QNRX Comparison
GVH vs QNRX Comparison
Compare GVH & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GVH | QNRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 9.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GVH | QNRX |
|---|---|---|
| Price | $1.01 | $7.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | 116.1K | ★ 888.7K |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $3.25 |
| 52 Week High | $6.46 | $41.80 |
Technical Indicators
Market Signals| Indicator | GVH | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 72.33 |
| Support Level | $0.87 | $7.00 |
| Resistance Level | $1.13 | $8.61 |
| Average True Range (ATR) | 0.05 | 0.75 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 13.33 | 71.51 |
Price Performance
Historical ComparisonAbout GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.